Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629699 | 0.92 | CA1 (0.49) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL9489661 | 0.90 | CA1 (0.50) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL9489644 | 0.90 | CA1 (0.50) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL2722414 | 0.88 | DTYMK (0.51) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL14298925 | 0.86 | DTYMK (0.53) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL30309517 | 0.83 | ALDH1A1 (0.59) | CA1CA2DTYMKALDH1A1GPR35 | |
| SCHEMBL30309450 | 0.83 | ALDH1A1 (0.59) | CA1CA2DTYMKALDH1A1GPR35 | |
| SCHEMBL31229767 | 0.83 | CDK2 (0.47) | CA1CA2DTYMKCDK2ALDH1A1 | |
| SCHEMBL11835122 | 0.82 | GPR35 (0.60) | CA1CA2ALDH1A1GPR35SMN1; SMN2 | |
| SCHEMBL28405537 | 0.80 | SNCA (0.43) | CA1CA2DTYMKCDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377907-B | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20130011465-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130011465-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236983-B2 | Composition and method for the treatment of diseases affected by apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236983-B2 | Composition and method for the treatment of diseases affected by apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-07 | — | — | US | disclosed |
| US-7816324-B2 | Composition and method for the treatment of diseases affected by a peptide receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010083215-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100178324-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | Board of Regents, The University System (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178324-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | Board of Regents, The University System (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178324-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BAX, BAD, BID | CA1 1545/4885CA2 2825/4885DTYMK 1854/4885 |
| US-20130011465-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS | BAX, BAD, BID | CA1 1545/4885CA2 2825/4885DTYMK 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.